Clinical Trials Logo

Barrett's Esophagus clinical trials

View clinical trials related to Barrett's Esophagus.

Filter by:

NCT ID: NCT02947971 Recruiting - Barrett's Esophagus Clinical Trials

Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System

Start date: April 15, 2016
Phase: N/A
Study type: Interventional

The goal of this research is to test a distal scanning capsule and a compact redesigned version of the OFDI imaging system in healthy and BE subjects to assess ease of use, safety and feasibility in preparation for its use in a multicenter clinical trial.

NCT ID: NCT02922049 Completed - Barrett's Esophagus Clinical Trials

pCLE in the Detection of Esophageal and Gastric Lesions and Intestinal Metaplasia or Dysplasia in Patients After Endoscopic Treatment of BORN

Start date: April 2016
Phase: N/A
Study type: Interventional

To assess diagnostic accuracy and clinical effectiveness including cost-effectiveness analysis of pCLE in patients after finishing the endoscopic treatment of BORN in detecting persistent/recurrent IM, recurrent neoplasia and buried glands.

NCT ID: NCT02879721 Completed - Barrett's Esophagus Clinical Trials

Expression and Function of the Renin-Angiotensin System in the Esophagus

Start date: October 2009
Phase: Phase 0
Study type: Interventional

Barrett`s esophagus (BE) is the major esophageal pre-neoplastic lesion in which dysplastic transformations eventually can lead to cancer development. Today, the only way for early detection of pre-neoplastic lesions is an endoscopic surveillance programme with tissue sampling for histopathology, the latter being the only validated biomarker for esophageal adenocarcinoma (EAC)-risk available. New biomarkers are warranted for better patient selection before inclusion into BE surveillance programmes. Epidemiologic studies have demonstrated suppressed numbers of cancer prevalence in cohorts being under different medical treatment. In a British epidemiological study 2007 Sjöberg et al noted a lower prevalence of EAC among patients treated with antihypertensive drugs interfering with the renin-angiotensin system (RAS) such as AT1R-blockers and ACE-inhibitors. The last decade this endocrine signalling system has been proven to be involved in pathological conditions such as inflammation, wound-healing and even cancer, in several organ systems. Earlier reports from the investigators laboratory indicate the existence of a local RAS in the esophageal wall musculature and in the squamous mucosa. In the investigators latest explorative study, the investigators discovered the altered expression of "classical" RAS components in BE with and without dysplasia (unpublished results). By a possible alteration in RAS-related protein-expression in BE with increasing grade of dysplasia towards EAC, the investigator may have a possible "pathway" leading to biomarkers for cancer-development. Furthermore, the already well-known anti-hypertensive drugs ACE-inhibitors and AT1R-blockers may interfere with the risk of malignancy in BE. The investigators therefore wish to test, in an exploratory prospective randomized placebo-controlled setting, whether RAS-related protein-expressions in BE are altered by the addition of RAS-suppressant pharmaceuticals. In the same manner the investigators wish to see if the expressions of well-known biomarkers for cancer and inflammation are altered.

NCT ID: NCT02864043 Active, not recruiting - Barrett's Esophagus Clinical Trials

Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System

DDP
Start date: September 2016
Phase: N/A
Study type: Interventional

The NvisionVLE® Dysplasia Detection Pilot Study is a prospective, non-randomized trial for participants who have a prior biopsy-confirmed diagnosis of BE with dysplasia and are scheduled to have an endoscopic evaluation of your esophagus for BE surveillance by a standard procedure called EGD (esophagogastroduodenoscopy) as well as an imaging procedure called VLE (volumetric laser endomicroscopy).

NCT ID: NCT02852525 Completed - Barrett's Esophagus Clinical Trials

Confocal Laser Probe to Treat Barrett's Esophagus

pCLE
Start date: February 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to further validate the use of probe-based confocal laser endomicroscopy (pCLE) for the evaluation of Barrett's Esophagus and associated neoplasia in a larger patient base.

NCT ID: NCT02793479 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Radiofrequency Ablation in Patients With Barrett's Esophagus

RABE
Start date: March 1, 2017
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to establish a nationwide registry to collect data regarding the treatment of Barrett's Esophagus (BE) with radiofrequency ablation. The objective of this registry is to increase the number of data and therefore obtain a raise of quality assurance and improve outcome and patient security. Furthermore to provide participating physicians information and experience for treatment details in the therapy of BE.

NCT ID: NCT02634645 Recruiting - Esophageal Cancer Clinical Trials

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

Start date: January 2015
Phase:
Study type: Observational

A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).

NCT ID: NCT02632682 Completed - Barrett's Esophagus Clinical Trials

Confocal Laser Endomicroscopy vs Conventional Histology for the Identification of Intestinal Metaplasia

Start date: February 2016
Phase: N/A
Study type: Observational

Real-time Diagnosis of Barrett's Esophagus: Comparing Confocal Laser Endomicroscopy with Conventional Histology for the Identification of Specialized Intestinal Metaplasia

NCT ID: NCT02614703 Terminated - Barrett's Esophagus Clinical Trials

"Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance

Start date: March 10, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Neoplasia in Barrett's esophagus could be missed during routine random biopsies. We propose a study using chromoendoscopy with Acetic Acid to increase the yield of biopsies in detecting neoplasia.

NCT ID: NCT02597712 Completed - Barrett's Esophagus Clinical Trials

YF476 in Barrett's Esophagus

Start date: May 15, 2013
Phase: Phase 2
Study type: Interventional

A phase 2, randomised, double-blind, out-patient trial to determine if YF476 is a safe and effective treatment in patients with Barrett's esophagus.